Comparative Pharmacology
Head-to-head clinical analysis: DIFLUNISAL versus NAPROXEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUNISAL versus NAPROXEN.
DIFLUNISAL vs NAPROXEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
500 mg to 1000 mg orally initially, then 250 mg to 500 mg every 8 to 12 hours. Maximum daily dose: 1500 mg.
250-500 mg orally twice daily; maximum 1.5 g/day. For extended-release: 750-1000 mg orally once daily.
MODERATE Risk
MODERATE Risk
Clinical Note
moderateDiflunisal + Gatifloxacin
"Diflunisal may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateNaproxen + Gatifloxacin
"Naproxen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateDiflunisal + Rosoxacin
"Diflunisal may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateNaproxen + Rosoxacin
"Naproxen may increase the neuroexcitatory activities of Rosoxacin."
8-12 hours (prolonged in renal impairment; clinical context: permits twice-daily dosing)
Terminal elimination half-life 12-17 hours (mean 14 hours); permits twice-daily dosing. Half-life prolonged in elderly and hepatic impairment.
Renal (90% as glucuronide conjugates, <5% unchanged); biliary/fecal (<10%)
Primarily renal (95% as unchanged naproxen and 6-O-desmethylnaproxen); <5% fecal via biliary excretion.
Category C
Category D/X
NSAID
NSAID